Strategic Approaches to Optimizing Peptide ADME Properties

AAPS Journal

Volumn 17, Issue 1, 2015, Pages 134-143

  Di, Li ^a  

^a PFIZER INC   (United States)

Author keywords

ADME; peptides; pharmacokinetics; proteolysis; renal clearance

Indexed keywords

CYCLOSPORIN A; LEUPRORELIN; LIRAGLUTIDE; OCTREOTIDE; PEGINESATIDE; PENETRATION ENHANCING AGENT; PEPTIDE; PLASMA PROTEIN; PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANEMIA; ARTICLE; CONJUGATION; CONTROLLED DRUG RELEASE; COVALENT BOND; CYCLIZATION; DISULFIDE BOND; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; ENDOCRINE TUMOR; ENDOMETRIOSIS; HUMAN; HYDROGEN BOND; INTRINSIC CLEARANCE; KIDNEY CLEARANCE; MEMBRANE PERMEABILITY; NONHUMAN; PHARMACODYNAMICS; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; PREDICTION; PROSTATE CANCER; PROTEIN DEGRADATION; STEREOSPECIFICITY; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG APPROVAL; DRUG DESIGN; HALF LIFE TIME; PERMEABILITY; SOLUBILITY;

ANIMALS; COMPUTER SIMULATION; DRUG APPROVAL; DRUG DESIGN; HALF-LIFE; HUMANS; PEPTIDES; PERMEABILITY; SOLUBILITY;

EID: 84922005015     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9687-3     Document Type: Article

References (121)

1. Hopkins AL, Groom CR. Opinion: the druggable genome. Nat Rev Drug Discov. 2002;1(9):727–30.
2. Gongora-Benitez M, Tulla-Puche J, Albericio F. Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chem Rev (Washington, DC, U S). 2014;114(2):901–26.
3. Sun L. Peptide-based drug development. Mod Chem Appl. 2013;1(1):1–2.
4. Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. Curr Med Chem. 2012;19(26):4451–61.
5. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136–47.
6. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18(17–18):807–17.
7. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1/2):40–56.
8. Ladner RC, Sato AK, Gorzelany J, De Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today. 2004;9(12):525–9.
9. Lax R, Meenan C. Challenges for therapeutic peptides part 1: on the inside, looking out. Innovations Pharm Technol. 2012;42:54–6.
10. Lax R, Meenan C. Challenges for therapeutic peptides part 2: delivery systems. Innovations Pharm Technol. 2012;43:42–4. 6.
11. Bray BL. Innovation: large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587–93.
12. Edmonds DJ, Price DA. Oral GLP-1 modulators for the treatment of diabetes. Annu Rep Med Chem. 2013;48:119–30.
13. Rezai T, Bock JE, Zhou MV, Kalyanaraman C, Lokey RS, Jacobson MP. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J Am Chem Soc. 2006;128(43):14073–80.
14. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2–3):153–214.
15. Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52(10):855–68.
16. Rand AC, Leung SSF, Eng H, Rotter CJ, Sharma R, Kalgutkar AS, et al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance. Med Chem Comm. 2012;3(10):1282–9.
17. Werle M, Bernkop-Schnuerch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351–67.
18. Zhou XH, Li Wan Po A. Peptide and protein drugs: II. Non-parenteral routes of delivery. Int J Pharm. 1991;75(2–3):117–30.
19. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther (St Louis). 1996;60(6):601–7.
20. Maher S, Brayden DJ. Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov Today: Technol. 2012;9(2):e113–e9.
21. Chin J, Foyez Mahmud KA, Kim SE, Park K, Byun Y. Insight of current technologies for oral delivery of proteins and peptides. Drug Discov Today: Technol. 2012;9(2):e105–e12.
22. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009;10(7):661–91.
23. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485–504.
24. Munegumi T. Hydrophobicity of peptides containing D-amino acids. Chem Biodivers. 2010;7(6):1670–9.
25. Ano R, Kimura Y, Shima M, Matsuno R, Ueno T, Akamatsu M. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg Med Chem. 2004;12(1):257–64.
26. Kramer SD, Wunderli-Allenspach H. No entry for TAT(44–57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides. Biochim Biophys Acta Biomembr. 2003;1609(2):161–9.
27. Tang F, Borchardt RT. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res. 2002;19(6):787–93.
28. Ano R, Kimura Y, Urakami M, Shima M, Matsuno R, Ueno T, et al. Relationship between structure and permeability of dipeptide derivatives containing tryptophan and related compounds across human intestinal epithelial (Caco-2) cells. Bioorg Med Chem. 2004;12(1):249–55.
29. Stevenson CL, Augustijns PF, Hendren RW. Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. Int J Pharm. 1999;177(1):103–15.
30. Beck JG, Chatterjee J, Laufer B, Kiran MU, Frank AO, Neubauer S, et al. Intestinal permeability of cyclic peptides: common key backbone motifs identified. J Am Chem Soc. 2012;134(29):12125–33.
31. Bhardwaj RK, Herrera-Ruiz D, Sinko PJ, Gudmundsson OS, Knipp G. Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther. 2005;314(3):1093–100.
32. Faria TN, Timoszyk JK, Stouch TR, Vig BS, Landowski CP, Amidon GL, et al. A novel high-throughput PepT1 transporter assay differentiates between substrates and antagonists. Mol Pharm. 2004;1(1):67–76.
33. Balimane PV, Chong S, Patel K, Quan Y, Timoszyk J, Han Y-H, et al. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharmacal Res. 2007;30(4):507–18.
34. Vadlapudi AD, Vadlapatla RK, Mitra AK. Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. Curr Drug Targets. 2012;13(7):994–1003.
35. Stenberg P, Luthman K, Artursson P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharm Res. 1999;16(2):205–12.
36. Rafi SB, Hearn BR, Vedantham P, Jacobson MP, Renslo AR. Predicting and improving the membrane permeability of peptidic small molecules. J Med Chem. 2012;55(7):3163–9.
37. Jappar D, Hu Y, Smith DE. Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos. 2011;39(12):2250–7.
38. Li W, Zhang J, Tse FLS. Handbook of LC-MS bioanalysis: best practices, experimental protocols, and regulations 2013.
39. Letzel T, Editor. Protein and peptide analysis by LC-MS: experimental strategies. [In: RSC Chromatogr. Monogr., 2011; 15]2011. 172 pp.
40. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2008;872(1–2):1–22.
41. Li W, Zhang J, Tse FLS. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr. 2011;25(1–2):258–77.
42. Nowatzke WL, Rogers K, Wells E, Bowsher RR, Ray C, Unger S. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis. 2011;3(5):509–21.
43. Kuhn B, Mohr P, Stahl M. Intramolecular hydrogen bonding in medicinal chemistry. J Med Chem. 2010;53(6):2601–11.
44. Lokey RS. Testing the conformational hypothesis of membrane permeability using cyclic peptide diastereomers. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept 10–14, 2006. 2006:BIOL-167.
45. Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J Am Chem Soc. 2006;128(8):2510–1.
46. White TR, Renzelman CM, Rand AC, Rezai T, McEwen CM, Gelev VM, et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat Chem Biol. 2011;7(11):810–7.
47. Alex A, Millan DS, Perez M, Wakenhut F, Whitlock GA. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med Chem Comm. 2011;2(7):669–74.
48. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17(15–16):850–60.
49. Tressel SL, Koukos G, Tchernychev B, Jacques SL, Covic L, Kuliopulos A. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol (N Y, NY, U S). 2011;683:259–75. Cell-Penetrating Peptides.
50. Wang J, Shen D, Shen W-C. Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated antidiuretic activity. Pharm Res. 1999;16(11):1674–9.
51. Wang J, Chow D, Heiati H, Shen W-C. Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release. 2003;88(3):369–80.
52. Wang J, Shen W-C. Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice. Int J Pharm. 2000;204(1–2):111–6.
53. Chae SY, Jin C-H, Shin HJ, Youn YS, Lee S, Lee KC. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjugate Chem. 2008;19(1):334–41.
54. Clardy-James S, Chepurny OG, Leech CA, Holz GG, Doyle RP. Synthesis, characterization and pharmacodynamics of vitamin-B12-conjugated glucagon-like peptide-1. ChemMedChem. 2013;8(4):582–6.
55. Clardy SM, Allis DG, Fairchild TJ, Doyle RP. Vitamin B12 in drug delivery: breaking through the barriers to a B12 bioconjugate pharmaceutical. Expert Opin Drug Deliv. 2011;8(1):127–40.
56. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269–77.
57. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci. 2000;89(4):429–42.
58. Whitehead K, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm Res. 2008;25(8):1782–8.
59. LeCluyse EL, Sutton SC. In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv Drug Deliv Rev. 1997;23(1–3):163–83.
60. Wang X, Maher S, Brayden DJ. Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate. Ther Deliv. 2010;1(1):75–82.
61. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–95.
62. Puente XS, Gutierrez-Fernandez A, Ordonez GR, Hillier LW, Lopez-Otin C. Comparative genomic analysis of human and chimpanzee proteases. Genomics. 2005;86(6):638–47.
63. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994;11(2–3):61–95.
64. Powell MF, Grey H, Gaeta F, Sette A, Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci. 1992;81(8):731–5.
65. Powell MF, Stewart T, Otvos Jr L, Urge L, Gaeta FCA, Sette A, et al. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res. 1993;10(9):1268–73.
66. Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, Wade JD, et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 2008;17(7):1249–55.
67. Eng H, Sharma R, McDonald TS, Landis MS, Stevens BD, Kalgutkar AS. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9–36)amide in male Beagle dogs. Xenobiotica. 2014;44(9):842–8.
68. Sharma R, McDonald TS, Eng H, Limberakis C, Stevens BD, Patel S, et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9–36)amide and GLP-1(28–36)amide in mouse and human hepatocytes. Drug Metab Dispos. 2013;41(12):2148–57.
69. Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9(9):963–78.
70. Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE, et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers. 2008;90(5):671–82.
71. Ovadia O, Linde Y, Haskell-Luevano C, Dirain ML, Sheynis T, Jelinek R, et al. The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. Bioorg Med Chem. 2010;18(2):580–9.
72. Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem. 2008;51(4):1026–34.
73. Byk G, Halle D, Zeltser I, Bitan G, Selinger Z, Gilon C. Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem. 1996;39(16):3174–8.
74. Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. Med Chem Comm. 2010;1(5):319–24.
75. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99(6):2557–75.
76. Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 2006;17(6):638–42.
77. John H, Maronde E, Forssmann W-G, Meyer M, Adermann K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7–34)-amide from DPP-IV-mediated degradation retaining cAMP-and insulin releasing capacity. Eur J Med Res. 2008;13(2):73–8.
78. Stroemstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother. 2009;53(2):593–602.
79. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49–58.
80. Sharman A, Low J. Vasopressin and its role in critical care. Contin Educ Anaesth, Crit Care Pain. 2008;8(4):134–7.
81. Agerso H, Larsen LS, Riis A, Lovgren U, Karlsson MO, Senderovitz T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004;58(4):352–8.
82. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl):S1–4.
83. Chen S, Gfeller D, Buth SA, Michielin O, Leiman PG, Heinis C. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. Chem Bio Chem. 2013;14(11):1316–22.
84. Tugyi R, Uray K, Ivan D, Fellinger E, Perkins A, Hudecz F. Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A. 2005;102(2):413–8.
85. Darlak K, Benovitz DE, Spatola AF, Grzonka Z. Dermorphin analogs: resistance to in vitro enzymatic degradation is not always increased by additional D-amino acid substitutions. Biochem Biophys Res Commun. 1988;156(1):125–30.
86. Rafferty B, Coy DH, Poole S. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1–29)-amide. Peptides. 1988;9(1):207–9.
87. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5(12):1034–49.
88. Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol. 2010;84(21):11235–44.
89. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003;90(3):552–9.
90. Heredi-Szabo K, Murphy RF, Lovas S. Is IGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells? J Pept Sci. 2006;12(11):714–20.
91. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61.
92. Gobburu JVS, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–6.
93. Weber SJ, Greene DL, Hruby VJ, Yamamura HI, Porreca F, Davis TP. Whole body and brain distribution of [3H]cyclic [D-Pen2, D-Pen5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J Pharmacol Exp Ther. 1992;263(3):1308–16.
94. Tugyi R, Mezo G, Fellinger E, Andreu D, Hudecz F. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide. J Pept Sci. 2005;11(10):642–9.
95. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (Washington, DC, U S). 2004;305(5689):1466–70.
96. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide [Erratum to document cited in CA146:397011]. J Am Chem Soc. 2007;129(16):5298.
97. Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010;107(32):14093–8. S/1-S/8.
98. Grigoryev Y. Stapled peptide to enter human testing, but affinity questions remain. Nat Med (N Y, NY, U S). 2013;19(2):120.
99. Czock D, Keller F, Seidling HM. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol. 2012;74(1):66–74.
100. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73.
101. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet. 1993;25(5):375–91.
102. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol Suppl. 1986;119:65–72.
103. Malm-Erjefalt M, Bjoernsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944–53.
104. Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2012;32(12):2201–10.
105. Levy Odile E, Jodka Carolyn M, Ren Shijun S, Mamedova L, Sharma A, Samant M, et al. Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS One. 2014;9(2):e87704.
106. Lindgren J, Refai E, Zaitsev Sergei V, Abrahmsen L, Berggren P-O, Karlstrom AE. A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life. Biopolymers. 2014;102(3):252–9.
107. Angelini A, Morales-Sanfrutos J, Diderich P, Chen S, Heinis C. Bicyclization and tethering to albumin yields long-acting peptide antagonists. J Med Chem. 2012;55(22):10187–97.
108. Bronson J, Black A, Dhar TGM, Ellsworth BA, Merritt JR. To market, to market—2012. Annu Rep Med Chem. 2013;48:471–546.
109. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology. 2008;134(4):1137–47.
110. Poole RM, Nowlan ML. Albiglutide: first global approval. Drugs. 2014:Ahead of Print.
111. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–97.
112. Delaforgea M, Bouille G, Jaouen M, Jankowski CK, Lamouroux C, Bensoussan C. Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450. Peptides (N Y, NY, U S). 2001;22(4):557–65.
113. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87(11):1322–30.
114. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005;33(6):771–7.
115. Di L, Feng B, Goosen TC, Lai Y, Steyn SJ, Varma MV, et al. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos. 2013;41(12):1975–93.
116. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31(4):253–63.
117. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8(11):1351–9.
118. Richter WF, Gallati H, Schiller C-D. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos. 1999;27(1):21–5.
119. Grene-Lerouge NAM, Bazin-Redureau MI, Debray M, Scherrmann JMG. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol. 1996;138(1):84–9.
120. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93(1):177–85.
121. Chen T, Mager DE, Kagan L. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res. 2013;30(3):751–60.